Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 24.42
XON's Cash-to-Debt is ranked lower than
52% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. XON: 24.42 )
Ranked among companies with meaningful Cash-to-Debt only.
XON' s Cash-to-Debt Range Over the Past 10 Years
Min: 9.17  Med: 30.36 Max: N/A
Current: 24.42
Equity-to-Asset 0.58
XON's Equity-to-Asset is ranked lower than
60% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. XON: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
XON' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.12  Med: 0.67 Max: 0.8
Current: 0.58
-2.12
0.8
Piotroski F-Score: 4
Altman Z-Score: 2.90
Beneish M-Score: -2.74
WACC vs ROIC
17.98%
-30.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -57.65
XON's Operating Margin % is ranked higher than
53% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. XON: -57.65 )
Ranked among companies with meaningful Operating Margin % only.
XON' s Operating Margin % Range Over the Past 10 Years
Min: -1028.67  Med: -170.73 Max: -57.65
Current: -57.65
-1028.67
-57.65
Net Margin % -76.32
XON's Net Margin % is ranked lower than
52% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. XON: -76.32 )
Ranked among companies with meaningful Net Margin % only.
XON' s Net Margin % Range Over the Past 10 Years
Min: -1064.27  Med: -138.91 Max: -48.67
Current: -76.32
-1064.27
-48.67
ROE % -25.83
XON's ROE % is ranked higher than
54% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. XON: -25.83 )
Ranked among companies with meaningful ROE % only.
XON' s ROE % Range Over the Past 10 Years
Min: -254.03  Med: -25.77 Max: -15.66
Current: -25.83
-254.03
-15.66
ROA % -15.79
XON's ROA % is ranked higher than
59% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. XON: -15.79 )
Ranked among companies with meaningful ROA % only.
XON' s ROA % Range Over the Past 10 Years
Min: -74.27  Med: -17.49 Max: -10.84
Current: -15.79
-74.27
-10.84
ROC (Joel Greenblatt) % -284.63
XON's ROC (Joel Greenblatt) % is ranked higher than
51% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. XON: -284.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
XON' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -460.38  Med: -284.8 Max: -160.11
Current: -284.63
-460.38
-160.11
3-Year Revenue Growth Rate 40.80
XON's 3-Year Revenue Growth Rate is ranked higher than
83% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. XON: 40.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
XON' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22  Med: -14.4 Max: 40.8
Current: 40.8
-22
40.8
3-Year EBITDA Growth Rate 21.10
XON's 3-Year EBITDA Growth Rate is ranked higher than
72% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. XON: 21.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
XON' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.2  Med: -63.4 Max: 21.1
Current: 21.1
-64.2
21.1
3-Year EPS without NRI Growth Rate 4.10
XON's 3-Year EPS without NRI Growth Rate is ranked higher than
58% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. XON: 4.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
XON' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65.7  Med: -64.7 Max: 4.1
Current: 4.1
-65.7
4.1
GuruFocus has detected 2 Warning Signs with Intrexon Corp $XON.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XON's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

XON Guru Trades in Q2 2016

Murray Stahl 17,439 sh (New)
John Burbank 19,981 sh (New)
Joel Greenblatt 28,320 sh (+21.64%)
George Soros Sold Out
Chase Coleman Sold Out
First Eagle Investment 1,102,004 sh (-7.19%)
» More
Q3 2016

XON Guru Trades in Q3 2016

First Eagle Investment 1,102,004 sh (unchged)
John Burbank Sold Out
Joel Greenblatt Sold Out
Murray Stahl 14,592 sh (-16.33%)
» More
Q4 2016

XON Guru Trades in Q4 2016

Murray Stahl 16,416 sh (+12.50%)
First Eagle Investment 1,102,004 sh (unchged)
» More
Q1 2017

XON Guru Trades in Q1 2017

Murray Stahl 21,075 sh (+28.38%)
First Eagle Investment 1,102,004 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with XON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:OTCPK:ABCZF, NAS:JUNO, NAS:SAGE, NAS:ICPT, NAS:RARE, NAS:CLVS, NAS:AGIO, NYSE:AXON, NAS:LGND, NAS:PBYI, NAS:CBPO, OTCPK:MPSYY, NAS:PTLA, NAS:AVXS, NAS:ACAD, NAS:BLUE, NAS:NKTR, OTCPK:BTGGF, NAS:TBPH, NAS:PRTA » details
Traded in other countries:I5X.Germany,
Headquarter Location:USA
Intrexon Corp is a synthetic biology company that designs, builds and regulates gene programs using its proprietary and complementary technologies.

Intrexon is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Top Ranked Articles about Intrexon Corp

ZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock
Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy
Fibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia
ZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities
ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1, 2017 at 4:30 p.m. ET
ZIOPHARM Oncology to Present Updated Clinical Results of Gene Therapy Candidate Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting
Fibrocell to Present at 7th Annual World Orphan Drug Congress USA 2017 and 5th Annual Cell & Gene Therapy Investor Day
Intrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR-T Platform Empowered by Membrane-Bound IL-15 Under RheoSwitch Therapeutic System® Control

Ratios

vs
industry
vs
history
PB Ratio 4.95
XON's PB Ratio is ranked lower than
55% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. XON: 4.95 )
Ranked among companies with meaningful PB Ratio only.
XON' s PB Ratio Range Over the Past 10 Years
Min: 3.54  Med: 5.54 Max: 14.93
Current: 4.95
3.54
14.93
PS Ratio 12.89
XON's PS Ratio is ranked higher than
51% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. XON: 12.89 )
Ranked among companies with meaningful PS Ratio only.
XON' s PS Ratio Range Over the Past 10 Years
Min: 5.83  Med: 18.56 Max: 67.17
Current: 12.89
5.83
67.17
EV-to-EBIT -15.40
XON's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. XON: -15.40 )
Ranked among companies with meaningful EV-to-EBIT only.
XON' s EV-to-EBIT Range Over the Past 10 Years
Min: -4357.8  Med: -31.5 Max: -12.1
Current: -15.4
-4357.8
-12.1
EV-to-EBITDA -18.46
XON's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. XON: -18.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
XON' s EV-to-EBITDA Range Over the Past 10 Years
Min: -281.9  Med: -23.4 Max: 406.4
Current: -18.46
-281.9
406.4
Current Ratio 3.11
XON's Current Ratio is ranked lower than
58% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. XON: 3.11 )
Ranked among companies with meaningful Current Ratio only.
XON' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 4.1 Max: 10.49
Current: 3.11
0.81
10.49
Quick Ratio 2.90
XON's Quick Ratio is ranked lower than
57% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. XON: 2.90 )
Ranked among companies with meaningful Quick Ratio only.
XON' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.85 Max: 10.49
Current: 2.9
0.81
10.49
Days Inventory 131.03
XON's Days Inventory is ranked lower than
54% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. XON: 131.03 )
Ranked among companies with meaningful Days Inventory only.
XON' s Days Inventory Range Over the Past 10 Years
Min: 131.03  Med: 149.45 Max: 244.37
Current: 131.03
131.03
244.37
Days Sales Outstanding 35.73
XON's Days Sales Outstanding is ranked higher than
69% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. XON: 35.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
XON' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.91  Med: 26.75 Max: 73.99
Current: 35.73
0.91
73.99
Days Payable 46.64
XON's Days Payable is ranked lower than
56% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. XON: 46.64 )
Ranked among companies with meaningful Days Payable only.
XON' s Days Payable Range Over the Past 10 Years
Min: 28.36  Med: 50.2 Max: 118.77
Current: 46.64
28.36
118.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.90
XON's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. XON: -6.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XON' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -176.2  Med: -167.7 Max: -6.9
Current: -6.9
-176.2
-6.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 17.72
XON's Price-to-Tangible-Book is ranked lower than
84% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. XON: 17.72 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
XON' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.83  Med: 12.38 Max: 27.38
Current: 17.72
6.83
27.38
Price-to-Median-PS-Value 0.70
XON's Price-to-Median-PS-Value is ranked higher than
74% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. XON: 0.70 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
XON' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.39  Med: 1.03 Max: 3.42
Current: 0.7
0.39
3.42
Earnings Yield (Greenblatt) % -6.49
XON's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. XON: -6.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
XON' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -437.1  Med: 0 Max: 0
Current: -6.49
-437.1
0

More Statistics

Revenue (TTM) (Mil) $201.2
EPS (TTM) $ -1.29
Beta2.63
Short Percentage of Float33.77%
52-Week Range $18.41 - 32.58
Shares Outstanding (Mil)119.61
» More Articles for XON

Headlines

Articles On GuruFocus.com
Intrexon to Present at Upcoming Investor and Industry Conferences May 24 2017 
ZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock May 12 2017 
Intrexon and Darling to Build Commercial-scale Production of Insect-Based Advanced Feed Ingredients May 10 2017 
Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American So May 09 2017 
Huvepharma to Utilize Intrexon's Proprietary Fungal Expression Platform to Produce Key Animal Feed E May 09 2017 
Fibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Tria May 08 2017 
Intrexon to Announce First Quarter 2017 Financial Results on May 10th May 03 2017 
Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 20 May 03 2017 
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Rel May 02 2017 
ZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activit May 01 2017 

More From Other Websites
Intrexon to Present at Upcoming Investor and Industry Conferences May 24 2017
Intrexon Appoints Dr. Mark Carnegie-Brown as CEO of Oxitec May 18 2017
What You Missed in Intrexon's Quarterly Report May 18 2017
ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be... May 17 2017
Fibrocell to Present at Inaugural Cell & Gene Exchange 2017 May 17 2017
Edited Transcript of XON earnings conference call or presentation 10-May-17 8:30pm GMT May 17 2017
How these two Tampa Bay companies got the financing to grow their technology May 16 2017
Intrexon to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference May 15 2017
Intrexon's First-Quarter 2017 Revenue Lacks Diversification, but Help Is On the Way May 12 2017
Ziopharm Prices Secondary Offering May 12 2017
ZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock May 12 2017
Today's Research Reports on Stocks to Watch: Himax Technologies and Intrexon Corporation May 12 2017
Intrexon (XON) Q1 Loss Wider than Expected, Revenues Beat May 11 2017
Why Intrexon Is Soaring Today May 11 2017
Intrexon reports 1Q loss May 10 2017
Intrexon Announces First Quarter 2017 Financial Results May 10 2017
Intrexon and Darling to Build Commercial-scale Production of Insect-Based Advanced Feed Ingredients May 10 2017
Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights May 10 2017
Medical Services Stock Q1 Earnings on May 10: CRL, XON, INCR May 09 2017
Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American... May 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)